Video Experimental Relacionado

Updated: Jan 8, 2026

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

Estudio sobre el refuerzo farmacéutico mejorado para reducir el consumo de alcohol y tabaco (PERRAS): Protocolo para

Paola Palombo¹, Nicole Akana², Abigail Bowen²

¹Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States of America; Analytics and PsychoPharmacology Laboratory (APPL), Washington State University, Spokane, WA, United States of America; Program of Excellence in Addiction Research (PEAR), Washington State University, Spokane, WA, United States of America; Department of Community and Behavioral Health, Washington State University, Spokane, WA, United States of America; Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.

Contemporary clinical trials

|December 21, 2025

Resumen

Este estudio probó si la combinación de Manejo de Contingencias (CM) para el trastorno por uso de alcohol (TDAH) con Vareniclina mejora la abstinencia de alcohol y tabaco. El tratamiento integrado muestra resultados prometedores para reducir el cop uso en personas con TDAH.

Área de la Ciencia:

Medicina de la adicción
Psicología clínica
Neurociencia

Sus antecedentes:

El cop uso de alcohol y tabaco provoca una morbilidad y mortalidad significativas.
Los enfoques de tratamiento integrado pueden reducir eficazmente el uso de ambas sustancias.
No existen directrices actuales para el tratamiento de la coadicción al alcohol y al tabaco.

Objetivo del estudio:

Evaluar la efectividad de combinar el Manejo de Contingencias (CM) para el Trastorno por Uso de Alcohol (TDAH) con Vareniclina para dejar de fumar.
Reducir el consumo de alcohol y tabaco en personas con TDAH que fuman y buscan tratamiento.
Evaluar el efecto mediador de los dominios de Evaluación Neuroclínica de la Adicción (ANA) en los resultados del tratamiento.

Principales métodos:

205 participantes con TDAH que fumaban fueron aleatorizados en dos condiciones de 12 semanas: CM + Vareniclina o No Contingente (NC) + Vareniclina.
El grupo CM recibió recompensas condicionadas a muestras de alcohol negativas; el grupo NC recibió recompensas independientemente de la positividad del alcohol.
Los resultados primarios midieron la verificación objetiva de la abstinencia tres veces por semana durante la intervención, con seguimientos a los 1, 3 y 6 meses.

Principales resultados:

El estudio está diseñado para demostrar la eficacia del enfoque de tratamiento integrado.
La verificación objetiva de la abstinencia durante la fase de intervención de 12 semanas es el resultado principal.
Las evaluaciones de seguimiento evaluarán la abstinencia sostenida a los 1, 3 y 6 meses posteriores a la intervención.

Conclusiones:

Un tratamiento integrado que combina CM para el TDAH y Vareniclina muestra potencial para obtener beneficios significativos para la salud.
Este enfoque puede ayudar a identificar cómo las respuestas basadas en ANA influyen en los resultados del tratamiento.
Un tratamiento eficaz es crucial para una población prevalente con trastornos concurrentes de uso de alcohol y tabaco.

Palabras clave:

Trastorno por uso de alcohol Manejo de contingencias Abstinencia de tabaco Vareniclina Evaluación neuroclínica de la adicción

Más Videos Relacionados

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

Videos de Conceptos Relacionados

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Randomized Experiments

Randomized Experiments

The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...

Blinding

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...